Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of OPN-305 in healthy volunteers
NL-OMON38332Phase 1Active, not recruiting
- Sponsor
- Opsona Therapeutics
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammation and graft rejection comparing OPN-305 with Placebo (2 arms). Primary endpoints: Safety and tolerability and Dose and infusion time selection. Started Jun 2011; status: active, not recruiting.
02
Drugs
tomaralimab
03
Conditions
inflammationgraft rejection
Beyond the preview
Go deeper on NL-OMON38332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38332.